SCHEMBL18407955

SCHEMBL18407955

Cn1cc(S(N)(=O)=O)cc1C(=O)Nc1ccc(F)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.48
▸ LMNA P02545 3/20 0.48
▸ THRB P10828 2/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ SOS1 Q07889 1/20 0.48
▸ TP53 P04637 2/20 0.47
▸ RXFP1 Q9HBX9 1/20 0.47
▸ HTR2B P41595 1/20 0.46
▸ MAPT P10636 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ MAOA P21397 1/20 0.45
▸ MAOB P27338 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21727502 0.90 THRB (0.47) POLBLMNATHRBTDP1TP53
SCHEMBL18407885 0.90 MEN1 (0.50) POLBLMNATHRBTDP1TP53
SCHEMBL21727603 0.90 POLB (0.50) POLBLMNATHRBTDP1NPC1
SCHEMBL18408005 0.89 CA2 (0.59) POLBLMNATHRBTDP1NPC1
SCHEMBL30035560 0.88 POLB (0.49) POLBLMNATHRBTDP1NPC1
SCHEMBL16237502 0.88 POLB (0.49) POLBLMNATHRBTDP1NPC1
Hydrochloric Acid SCHEMBL28276030 0.88 POLB (0.51) POLBLMNATHRBTDP1NPC1
SCHEMBL18407909 0.87 TP53 (0.57) POLBLMNATHRBTDP1TP53
SCHEMBL21727607 0.87 CYP1A2 (0.48) POLBLMNATHRBTDP1TP53
SCHEMBL21727622 0.87 CA1 (0.54) POLBLMNATHRBTDP1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3121164-B1 SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2020-02-19 — — EP disclosed
US-10457638-B2 Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B JANSSEN SCIENCES IRELAND UC (IE) 2019-10-29 — — US disclosed
US-20180141905-A1 SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B JANSSEN SCIENCES IRELAND UC (IE) 2018-05-24 — — US disclosed
US-9884818-B2 Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B JANSSEN SCIENCES IRELAND UC (IE) 2018-02-06 — — US disclosed
EP-3121164-A1 SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B Janssen Sciences Ireland UC (IE) 2017-01-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141905-A1 SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B RB1, XDH, HBS1L POLB 795/4885LMNA 2665/4885THRB 3197/4885
US-10457638-B2 Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B RB1, XDH, HBS1L POLB 795/4885LMNA 2665/4885THRB 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback